Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Melanie D Swift; Laura E Breeher; Aaron J Tande; Christopher P Tommaso; Caitlin M Hainy; Haitao Chu; M Hassan Murad; Elie F Berbari; Abinash Virk

doi:10.1093/cid/ciab361

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379. doi: 10.1093/cid/ciab361.

Authors

Melanie D Swift¹, Laura E Breeher¹, Aaron J Tande², Christopher P Tommaso³, Caitlin M Hainy¹, Haitao Chu⁴, M Hassan Murad¹, Elie F Berbari², Abinash Virk²

Affiliations

¹ Division of Preventive, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
³ Occupational Health Services, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Division of Biostatistics, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA.

Abstract

In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.

Keywords: COVID-19; SARS-CoV-2; healthcare personnel; mRNA; vaccine effectiveness.

MeSH terms

COVID-19 Vaccines
COVID-19*
Delivery of Health Care
Humans
RNA, Messenger
SARS-CoV-2
United States / epidemiology
Vaccines*

Substances

COVID-19 Vaccines
RNA, Messenger
Vaccines